Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furanyl fentanyl is a **synthetic opioid analgesic** and a structural analog of fentanyl. It consists of the fentanyl core structure, with a furan-2-carboxamide group replacing the propionamide moiety of fentanyl. Like other fentanyl analogs, furanyl fentanyl acts as a **potent agonist at the mu-opioid receptor**, responsible for its powerful analgesic and sedative effects. Furanyl fentanyl is not used clinically and is considered a **designer drug** that has emerged on illicit drug markets. It is classified as a Schedule I controlled substance in the United States and other jurisdictions, indicating no accepted medical use and a high potential for abuse. Relative to fentanyl, furanyl fentanyl possesses similar or slightly lower potency, but significant toxicity and a high risk of overdose, including fatal respiratory depression. Its metabolism primarily involves amide hydrolysis and oxidative transformation of the furanyl ring[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furanyl fentanyl.